We compared the uptake, metabolism, and biological effects of tetraiodothyroacetic acid (Tetrac) and rTs in anterior pituitary cells with those of Tb and Ts. Cells were isolated from adult male Wistar rats and cultured for 3 days in medium with 10% fetal calf serum. Uptake was measured at 37 C in medium with 0.1% BSAfor ["'IlTetrai (200, 000 cpm; 240 pM) and [ 1z511Tb (100,000 cpm; 175 PM) or with 0.5% BSAfor r'2511rTq (100.000 cnm: 250 DM) and 112511TQ (50.000 cnm: 50 PM). The f&e fGac;on oiTet& ias 1% that ONTO (&&ed&m iitg 0.1 and with 0.5% BSA), and the free fraction of rTs was half that of Ts. Uptake of the four tracers increased sharply up to 1 h of incubation and then leveled off. Expressed as femtomoles per pM free hormone, uptake at equilibrium was 1.16 ? 0.16 (n = 6) for Tetrac, 0.15 2 0.01 (n = 6) for Ta, 0.023 ? 0.003 (n = 6) for rTs, and 0.21 ? 0.02 (n = 6) for Ts. Cell-associated radioactivity after incubation for 24 h with [4454] [4455] [4456] [4457] [4458] [4459] [4460] [4461] 1995) N ONTHYROIDAL illness (NTI) and fasting are characterized by a low serum Ts concentration and an elevated serum concentration of rTs, whereas the serum Th concentration is normal or eventually decreased (l-4). In the face of the low serum Ts and Td concentrations, the serum TSH level is inappropriately low (1, 2, 4, 5) .
Recently, it was proposed that changes in T4 metabolism during fasting and NTI, i.e. a shift from deiodination to increased conjugation or alanine side-chain alteration, may result in metabolites with a TSH-suppressing effect. The first to be evaluated was Ts sulfate (6), but this metabolite appeared to be biologically inactive at the pituitary level (7, 8) , perhaps because it does not enter the tissue (8) . The second to be tested was the acetic acid derivative of Ts, triiodothyroacetic acid (Triac) (9,101, which is rapidly taken up by the pituitary (11) and has a profound TSH-suppressing effect both irz vitro (11, 12) and in viuo (13, 14) . Like Triac, the acetic acid derivative of Te, tetraiodothyroacetic acid (Tetrac), was suggested to contribute to the suppression of TSH secretion during fasting and NT1 (10). Administration of Tetrac reduced the TSH response to TRH in euthyroid subjects (13). Furthermore, in fasting subjects, the serum Tetrac concentration was reported to increase 2-fold (15).
Although rTZ is not ascribed any biological activity, recent studies indicate that one of its metabolites 3,3'-diiodothyronine (3,3'-TJ stimulates the mitochondrial respiratory rate (16). A similar action has been reported for 3,5-T* (a product of Ts deiodination) (16, 17) , which, in addition, has been shown to suppress TSH secretion in rats (18). The pituitary contains the enzyme that deiodinates rTs (19), but before this can occur, rTs has to enter the pituitary cells.
The present study was undertaken to investigate 11 the uptake and metabolism of 1z51-labeled rT3 and Tetrac in cultured anterior pituitary cells compared to that of 1251-labeled Ts and T4; 2) the effects of unlabeled Tetrac and rTs on the uptake of [ 1z51]Ts; and 3) the effects of unlabeled Tetrac, rT3, 3,3'-TZ, and 3,5-TZ on TRH-induced TSH release. Finally, we evaluated the distribution of Triac and Tetrac among serum proteins as well as the free fraction of Triac and Tetrac in serum of control subjects and NT1 patients.
Materials
and Methods 

Free fractions of iodothyronine derivatives
The free fractions of 3,3'-TZ, Ts, rTs, Ta, Triac, and Tetrac in medium with 0.5% BSA are shown in Fig. 1 . The free fraction decreases as the number of iodine atoms in the compound increases, whereas a change in the alanine sidechain to acetic acid, as in Triac and Tetrac, decreases the free fraction by a factor 8 (Triac ZJS. TJ or 100 (Tetrac VS. TJ. The free fractions of Tetrac and T* in medium with 0.1% BSA amounted to 0.029 ? 0.001% (n = 3) and 3.33 ? 0.08% (n = 4), respectively, i.e. again a loo-fold difference. The free Ts fraction (3.61 2 0.05%; n = 12) did not change after the addition of 1 nM-1 &LM Ta, Triac, Tetrac, or rTa, but it increased to 4.53 ? 0.13% (n = 4), 4.51% (n = 2), 4.17 * 0.02% (n = 4), and 4.43 ? 0.09% (n = 4) after the addition of 10 PM Ta, Triac, Tetrac and rTa, respectively. (Fig, 2A) or as femtomoles per pM free hormone (Fig.  2B) . The uptake curve for [ *z51]Ts was similar to that previously described (11, 22) , showed a steep phase up to 1 h of incubation, and reached equilibrium between l-4 h of incubation (Fi .2A). At any time point of the experiment, the uptake of 1 lg51]rTs was only 3-4% of the uptake of [1z511T3 ( Fig. 2A , Zower curve). When expressed as femtomoles per PM free hormone, there was still a large difference between the uptake of the two hormones, but as the free fraction of rTa was half that of Ta, the values for rTa uptake were about 10% of those for Ta uptake (Fig. 2B) .
Similar comparisons were made for the uptake of [lz51]Tetrat and [iz51]T* in incubation medium with 0.1% BSA (Fig. 3) . Uptake of [1*51]Tb showed a steep phase up to 1 h of incubation and reached a plateau at 4 h of incubation (Fig. 3A , upper curve). Uptake of 11z511Tetrac, expressed as percent dose, was less than 0.15% at any time point of the incubation (Fig. 3A , Zower curve), and [iz51]Td uptake was about lo-fold higher at equilibrium (Fig. 3A, upper curve) . However, when the data were expressed as femtomoles per PM free hormone, the picture was precisely reversed; the maximum uptake of that of [lz51]T4 was 0.15 ? 0.01 (n = 6) fmol/pM free TJ (P < 0.001; Fig. 3B ). (Fig. 4) as well as the effects of unlabeled rTs and Tetrac on the 15-min uptake of [*251]Ts (Fig. 5) .
Metabolism of iodothyronines and Tetrac
The uptake of [1251]Ts was at any time point significantly reduced by the presence of 10 FM Tetrac or Triac, and the effects of these analogs were similar. The effects of Tetrac and Triac were approximately 35%, 45%, and 70% after 15 min, 1 h, and 4 h of incubation, respectively (all P < 0.001; Fig. 4) .
Measurements of ]12511Ts uptake in the linear part of the curve presented in Fig. 4 , i.e. after 15 min of incubation, can be used to study uptake at the level of the pituitary plasma membrane (22, 23). The effects of Tetrac and rTa at concentrations from 1 nM to 1 FM on the 15-min uptake of [1251]Ts were compared with those of unlabeled Ta. The effect of unlabeled Ta increased progressively with the concentration, reaching a maximum of 68% suppression (P < 0.05) at 10 PM. In contrast, Tetrac and rTa did not affect [1251] Ts uptake up to a concentration of 1 PM, but reduced [1251]Ts uptake by about 45% (P < 0.05) at a concentration of 10 PM (Fig. 5) .
Effects on TRH-induced TSH release Table 3 shows the effects of Tetrac and rTa compared to those of Triac on TSH release during short term exposure to TRH. TSH release increased by approximately 90% after exposure to 100 nM TRH for 2 h (P < 0.05). This effect was SignificantIy reduced by preincubation (2 h) and incubation with Triac at a concentration as low as 0.01 nM (71% suppression; P < 0.05) and was fully blocked at concentrations of l-10 nM Triac and higher (P < 0.05). Preincubation and incubation with Tetrac resulted in a dose-dependent inhibition that was significant at 1 nM, and a maximum (82% inhibition; P < 0.05) was seen with a concentration of 1 PM. Preincubation and incubation with rTa showed a smaller inhibitory effect than that seen with Tetrac. Only at a rTa concentration of 1 PM was the TSH response to TRH significantly reduced (57%; P < 0.05). A direct comparison between Tetrac and Ta in a single experiment showed that 100 nM Tetrac reduced TRH-induced TSH release to the same extent as 10 nM T* (36% and 27% inhibition, respectively; Table 4 ).
Similarly, the effects of preincubation and incubation with 3,3'-Tz and 3,5-T2 were compared with those of Ta ( Table 5 ). The stimulation during short term exposure to 100 nM TRH was 133% (P < 0.05) in these experiments. Preincubation and incubation with Ts resulted in a dose-dependent inhibition of the TSH response to TRH, which was significant at concentrations of 1 nM and higher. 3,5-T2 reduced the TSH response significantly at a dose of 1 nM, and the effect of 100 nM 3,5-T2 was as great as that of 1 nM Ts (55% suppression; P < 0.05). 3,3'-T2 showed no inhibitory effect in doses less than 100 nM, but this dose had the same effect as 100 nM 3,5-T2 or 1 nM Ts.
Serum binding and free fraction of Triac and Tetrac
The binding of Triac and Tetrac to serum proteins was determined in four control subjects and four NT1 patients (Table 6 ). In control subjects, Triac was equally bound to albumin and TBPA, but in NT1 patients, more Triac was bound to albumin than to TBPA. Binding of Triac to TBG was negligible in both groups. In contrast, Tetrac was almost exclusively bound to TBPA in control subjects. Binding of Tetrac to albumin and TBG was about 5%. Also, the binding of Tetrac to TBPA was reduced in NT1 patients, whereas more Tetrac was bound to albumin than in the control subjects (Table 6 ).
The changes in serum binding during NT1 (Table 6 ) resulted in remarkable changes in the free fractions of Triac and Tetrac in NT1 patients (Fig. 6) . In control subjects (no. l-5), the free Triac fraction was approximately 0.04%, whereas that of Tetrac was 0.0011%. free Triac fraction increased 2-to B-fold, and that of Tetrac increased 2-to 12-fold.
Discussion
The present study shows that both [1z51]Tetrac and [1z511rT~ are taken up and metabolized in cultured anterior pituitary cells. In addition, Tetrac and its major metabolite Triac significantly reduced the TSH response to TRH at total hormone concentrations of 1 and 0.01 nM, respectively, whereas rTs and its metabolite 3,3'-TZ had to be added at total concentrations of 1 PM and 100 nM, respectively, to obtain a significant reduction of the TRH-induced TSH release. Expressed as percent dose, the uptake of [1z511Tetrac and [1251]rTs was very low. That both tracers were taken up by pituitary cells was indicated by the 24-h incubation experiments. Around 15% of the cell-associated radioactivity was these results indicated the presence of type II deiodinase activity in the cultured anterior pituitary cells (19) .
Because of the low tracer uptake of [iz51]rT~ and [iz51]Tetrat, it was impossible to test the effects of metabolic inhibitors and thyroid hormone analogs on the transport process. Therefore, we tested the effects of rTa and Tetrac on the uptake of [iz51]Tz. Neither rTa nor Tetrac had an effect on the 15-min uptake of [lz51]Ta when added at concentrations of l-100 nM, and both showed a significant reduction of [iz51]Ts uptake (45%) at a concentration of 1 /AM. In a previous study, the presence of 10 PM rTa reduced the 15-min uptake of [iz51]Td by 32%, whereas 10 ,uM Tetrac had no effect (23). As Ta and TJ probably share the same transport mechanism in The results obtained in the present and our previous study (23) do not argue against the possibility that rTa is taken up by the same transporter involved with Ta and Tb uptake. The conclusion for Tetrac is more complicated. The uptake of Tetrac per picomolar concentration of free hormone (-1 fmol) was as high as that of Triac (11). Furthermore, 10 FM Tetrac reduced the uptake of ]*z51]T3 (15 min to 4 h) to the same extent as 10 PM Triac. In our study of ]1z51]Triac uptake (11), it was concluded that at least part of Triac entered the pituitary by a mechanism different from the T3 transporter. Together, the similarities between Tetrac and Triac suggest that Tetrac enters the pituitary in the same way as Triac, i.e. at least partly by another mechanism than the Ta/Td transporter.
Tetrac was effective in reducing the TSH response to TRH at a total concentration of 1 nM, i.e. at a free concentration of 0.05 PM. 100 nM Tetrac showed the same inhibitory effect as IO nM Ta or 0.01 nM Triac. Corrected for the difference in free fraction in medium with 0.5% BSA (Tetrac, 0.005%; T*, 0.5%; Triac, 0.5%), 5 PM Tetrac was thus as effective as 50 PM T.+ or 0.05 PM Triac. In a direct comparison between Triac and Ta, it was estimated that Triac was 8 times more effective than Ta in reducing the TSH response to TRH (11). Thus, the order of potency for reducing TSH release in pituitary cells seems to be Triac > Ts > Tetrac > T+ The question remains of whether the effect of Tetrac or TJ on TSH release during 4 h of incubation is due to a direct effect or to an effect of their respective metabolites Triac and Ts. In a previous study on the metabolism of [iz51]Ta, it was found that iodide production into the medium after 6 h of incubation was about 40% of that found after 24 h (23). Assuming a similar value for Tetrac, and that a proportion- ally lower amount of J iz511Triac is formed after 6 h of incubation (-5%; i.e. 40% of 15% [*z51]Triac), this would mean that 10 nM Tetrac (in a volume of 0.5 ml = 5 pm011 with an uptake of 0.2% results in 0.5 fmol intracellular Triac within 6 h. Furthermore, 0.1 nM Triac (in a volume of 0.5 ml = 50 fmol), with an uptake of 1% (11) would result in 0.5 fmol intracellular Triac. As the effect of 10 nM Tetrac on TRHinduced TSH release was similar to that of 0.1 nM Triac, the effect of Tetrac on TRH-induced TSH release can be the result of its deiodination to Triac. rTa was only effective at a total concentration of 1 PM, whereas its metabolite 3,3'-Tz induced a significant reduction in TRH-stimulated TSH release at a total concentration of 100 niw In contrast, the Ta metabolite 3,5-Tz, showed a significant effect on TSH release at a concentration of 1 nM and was about loo-fold less effective than Ta. Thus, 3,5-Tz seems to be more effective in reducing TSH release than 3,3'-T?, whereas the two diiodothyronines were equally effective in stimulation of the mitochondrial respiratory rate (16). However, our results support the in vivo observations in rats, in which 3,5-Tz reduced TSH secretion at doses lo-to loo-fold higher than those of Ts (18).
The question of whether rTa or its metabolite 3,3'-Tz play a role in inhibition of TSH secretion during NT1 can be addressed as follows: the normal total serum levels of rTa and 3,3'-Tz are 0.40 and 0.11 nM (29). The same study showed that the serum total rTs concentration during NT1 rose to 0.66 nM, whereas that of 3,3'-Tz declined to 0.05 nM. This should be compared with the total hormone concentrations resulting in significant effects iyz vitro, i.e. 1 FM rTa and 100 nM 3,3'-Tz, respectively, in a medium containing 0.5% BSA where the free fraction will be at least lo-fold greater than that in serum. The difference between the effective concentrations jx vitro and those present in vivo is thus at least a factor of 10,000, which is not in favor of any biological significance of the two compounds in viva. The small inhibitory effect of rTa on TRH-induced TSH release cannot solely be explained by the low uptake of rTs by pituitary cells; compared with Ta, a lOOO-fold higher total concentration of rTa was required to reduce TSH release to the same extent (1 FM rTs vs. 1 nM Ta). In terms of free concentration, the difference will be a factor of 500 (free Ta fraction, 3.8%; free rTa fraction, 1.9%), whereas the difference in cellular uptake was a factor of 10.
The normal total serum Tetrac concentration varies between 0.7 nM (15) and 1.3 nM (13), With a free fraction of O.OOll%, the free Tetrac concentration in normal serum will be around 0.011 PM. As the production rate increases Z-fold in fasting (15) and the mean free fraction increases 7-fold during NTI, the resulting free concentration during fasting or NT1 will be about 0.15 PM. The lowest Tetrac concentration tested that reduced the response to TRH significantly was 1 nM, i.e. a free Tetrac concentration of 0.05 PM, which is of same order of magnitude as the free concentrations occurring in vivo.
Just as postulated for Triac, the low serum Tetrac concentration may be the result of the very effective glucuronidation in the liver (30). Although the free concentration of Tetrac in serum (0.01-0.15 PM; see above) is lower than that of Triac (0.02-0.3 PM; estimated from Refs. 9,11, and 31), Ta (2-4 PM) (3), or TJ (18-25 PM) (l-3), it is not excluded that Tetrac contributes to TSH suppression during NTI, because its uptake (per picomolar concentration of free hormone) into the pituitary is much larger than that of Ta and Th, whereas it is more effective than Td in reducing the TSH response to TRH. Also, the tentative conclusion that Tetrac (and Triac) are at least partly taken up in the pituitary by other transport mech-UPTAKE OF TETRAC AND rT3 [N PITUITARY CELLS 4461 anisms than Ts and T4 would support a possible role of the compound in vjvo. The large rise in the estimated free concentrations of Tetrac and Triac in patients with NT1 is not only due to the increase in the production rate (possibly 2-to 3-fold) (9, 151, but also to the rise in free fraction (2-to 12-fold; this study). The latter seems due to the fact that the level of TBPA, the most important binding protein for the two compounds in serum, strongly decreases during illness (101,
The conclusion of our study is that Tetrac and rTs, the serum concentration of which increases during fasting and NTI, are taken up and metabolized in cultured anterior pituitary cells. Only Tetrac reduces the TSH response to TRH jti vjfyo at concentrations comparable to those estimated Gz vjvo. Because Tetrac probably enters the pituitary through another transport system such as that described for Ts and T4, our results do not exclude a potential role for Tetrac in the inappropriately low serum TSH observed during NTI.
